The Journal of Urology
Volume 184, Issue 1 , Pages 81-86 , July 2010

Nonprimary pT1 Nonmuscle Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin is Associated With Higher Risk of Progression Compared to Primary T1 Tumors

  • Sultan S. Alkhateeb

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Bas W.G. Van Rhijn

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Antonio Finelli

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Theodorus van der Kwast

      Affiliations

    • Department of Pathology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Andrew Evans

      Affiliations

    • Department of Pathology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Sally Hanna

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Rati Vajpeyi

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Neil E. Fleshner

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Michael A.S. Jewett

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Alexandre R. Zlotta

      Affiliations

    • Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    • Mount Sinai Hospital, University of Toronto, Toronto, Canada
    • Corresponding Author InformationCorrespondence: Division of Urology, Department of Surgery, Mount Sinai Hospital and University Health Network, University of Toronto, 60 Murray St., 6th Floor, Box 19, Toronto, Ontario M5T 3L9, Canada (telephone: 416-586-4800 ext. 3910; FAX: 416-586-4776)

Received 15 November 2009

References 

  1. Saint F, Salomon L, Quintela R, et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? (Analysis of a quarter century of literature). Eur Urol. 2003;43:351
  2. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol. 2000;163:68
  3. Takashi M, Wakai K, Hattori T, et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol. 2002;33:41
  4. Hurle R, Losa A, Manzetti A, et al. Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology. 1999;54:258
  5. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53:992
  6. Akaza H, Hinotsu S, Aso Y, et al. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder (Four-year results. The Bladder Cancer BCG Study Group). Cancer. 1995;75:552
  7. Torrence RJ, Kavoussi LR, Catalona WJ, et al. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 1988;139:941
  8. Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992;148:797
  9. Pansadoro V, Emiliozzi P, de Paula F, et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology. 2002;59:227
  10. Okamura T, Tozawa K, Yamada Y, et al. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. J Urol. 1996;156:967
  11. Schrier BP, Hollander MP, van Rhijn BW, et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004;45:292
  12. El-Abbady AA, Shoukry MS, Hanno AG, et al. Repeated transurethral resection of recurrent superficial bladder tumors–does it affect the spread and stage of the tumor?. Scand J Urol Nephrol. 2002;36:60
  13. Cheng L, Neumann RM, Weaver AL, et al. Grading and staging of bladder carcinoma in transurethral resection specimens (Correlation with 105 matched cystectomy specimens). Am J Clin Pathol. 2000;113:275
  14. Dutta SC, Smith JA, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166:490
  15. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73
  16. Sylvester RJ, van derMeijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466

 Study received local research and ethics board approval.

 For other articles on a related topic see pages 336 and 344.

PII: S0022-5347(10)02995-2

doi: 10.1016/j.juro.2010.03.022

The Journal of Urology
Volume 184, Issue 1 , Pages 81-86 , July 2010

Article Tools

* Image Usage & Resolution